The Institute for Clinical and Economic Review (ICER) conducted a systematic literature review and cost-effectiveness analysis to evaluate
the health and economic outcomes of fezolinetant, MHT, antidepressants (selective serotonin reuptake inhibitors [SSRIs]/serotonin norepinephrine reuptake inhibitors [SNRIs]), and gabapentinoids (gabapentin and pregabalin) in women with moderate-to-severe VMS associated with menopause. We present the summary of our findings and highlights of the policy discussion with key stakeholders held at a public meeting of the Midwest Comparative Effectiveness Public Advisory Council (CEPAC) on December 16, 2022. The detailed
report is available on ICER’s website at https://icer.org/assessment/vasomotor-symptoms-menopause-2022/
